Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized, Controlled Trial in a Single Institution

References

1. Bruix J. Treatment of hepatocellular carcinoma. HEPATOLOGY 1997; 25: 259-262 [ Link previously at www.ncbi.nlm.nih.gov ].

2. Trinchet JC, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1997; 27: 756-765 [ Link previously at www.ncbi.nlm.nih.gov ].

3. Pelletier G, Roche A, Ink O, Anciaux L, Derhy S, Rougier P, Lenoir C, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184[ Medline].

4. Group d’Etude et de Traitement de Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261[ Medline].

5. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-136 [ Link previously at www.ncbi.nlm.nih.gov ].

6. Bruix J, Castells A, Montanyà X, Calvet X, Brú C, Ayuso C, Jover Ll, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. HEPATOLOGY 1994; 20: 643-650[.

7. Calvet X, Bruix J, Ginés P, Brú C, Solé M, Vilana R, Rodés J. Prognostic factors of hepatocellular carcinoma in the West: a multivariate analysis in 206 patients. HEPATOLOGY 1990; 12: 753-760.

8. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, Ayuso MC, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. HEPATOLOGY 1993; 18: 1121-1126].

9. Castells A, Bruix J, Brú C, Ayuso C, Roca M, Boix L, Vilana R, Rodés J. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-922.

10. Bruix J, Castells A, Bosch J, Feu F, Fuster J, García-Pagán JC, Visa J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-1022.

11. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Haregawwa H, Nakajima Y, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985; 56: 918-928[ Medline].

12. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67: 773-775 [ Link previously at www.ncbi.nlm.nih.gov ].

13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214 [ Link previously at www.ncbi.nlm.nih.gov ].

14. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-664 [ Link previously at www.ncbi.nlm.nih.gov ].

15. Arroyo V, Ginès P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. Am J Med 1986; 81: 104-122[ Medline].

16. Kalayci C, Johnson PJ, Raby N, Metivier EM, Williams R. Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J Hepatol 1990; 11: 349-353 [ Link previously at www.ncbi.nlm.nih.gov ].

17. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, et al. Prospective and randomized clinical trial for treatment of hepatocellular carcinoma. A comparison of lipiodol-transcatheter arterial embolization with and without adiamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992; 31(Suppl): S1-S6.

18. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994; 74: 2449-2453 [ Link previously at www.ncbi.nlm.nih.gov ].

19. Harris CC. Structure and function of the p53 tumor supressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-1455 [ Link previously at www.ncbi.nlm.nih.gov ].

20. Makuuchi M, Sukigara M, Mori T, Kobayashi J, Yamazaki S, Hasegawa H, Moriyama N, et al. Bile duct necrosis: complication of transcatheter arterial embolization. Radiology 1985; 156: 331-334[ Medline].

21. Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oil chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. HEPATOLOGY 1991; 13: 427-433].

22. Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8: 1108-1114[ Medline].

23. Stuart K, Stokes K, Jenkins R, Trey CH, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin ethiodized oil gelatin powder chemoembolization. Cancer 1993; 72: 3202-3209 [ Link previously at www.ncbi.nlm.nih.gov ].

24. Takayasu K, Suzuki M, Uesaka K, Muramatsu Y, Moriyama N, Yoshida T, Yoshino M, et al. Hepatic artery embolization for inoperable hepatocellular carcinoma: prognosis and risk factors. Cancer Chemother Pharmacol 1989; 23(Suppl): S123-S125[ Medline].

25. Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, Alberti A, et al. Transarterial oil chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. HEPATOLOGY 1994; 19: 1115-1123.

26. Bismuth H, Morino M, Sherlock D, Castaing D, Miglietta C, Cauquil P, Roche A. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992; 163: 387-394 [ Link previously at www.ncbi.nlm.nih.gov ].

27. Ikeda K, Kumada H, Saitho S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 1991; 68: 2150-2154 [ Link previously at www.ncbi.nlm.nih.gov ].

28. Miyoshi S, Minami Y, Kawata S, Imai Y, Sitoh S, Noda S, Tamura S, et al. Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma. Assessment by maximal removal of indocyanine green. J Hepatol 1988; 6: 332-336[ Medline].

29. Louha M, Poussin K, Ganne N, Zylberberg H, Nalpas B, Nicolet J, Capron F, et al. Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. HEPATOLOGY 1997; 26: 998-1005.

30. Boix L, Bruix J, Castells A, França A, Llovet JM, Rivera F, Rodés J. Circulating mRNA for alpha-fetoprotein in patients with hepatocellular carcinoma. Evidence of tumor dissemination after transarterial embolization. HEPATOLOGY 1996; 24: 349A.

31. Arora AS, deGroen PC, Croall DE, Emori Y, Gores GJ. Hepatocellular carcinoma cells during anoxia by preventing phospholipase-mediated calpain activation. J Cell Physiol 1996; 167: 434-442 [ Link previously at www.ncbi.nlm.nih.gov ].

32. Wang XW, Jia L, Sun Z, Harris C. Interactive effects of p53 tumor suppressor gene and hepatitis B virus in hepatocellular carcinoma. In: Arroyo V, Bosch J, Bruguera M, Rodés J, eds. Therapy in Liver Diseases. The Pathophysiological Basis of Therapy. Barcelona: Masson, 1997:471-478.

 

Return To Article